Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- 10 Jun 2017 Biomarkers information updated
- 07 Mar 2017 Status changed from active, no longer recruiting to completed.
- 07 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.